ABSTRACT
Objective To investigate the changes of T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). To evaluate the clinical efficacy of Xuebijing injection in the treatment of AECOPD and its influence on T lymphocyte subsets. Methods From October 2016 to October 2017, 58 AECOPD patients and 20 healthy subjects at the same period in the First People's Hospital of Luoyang were selected. The levels of T - lymphocyte subsets were detected in healthy subjects and AECOPD patients. The 58 cases patients were divided into observation group(n = 28) and control group(n = 30) using random number table. The control group was treated with conventional therapy. The observation group was treated with Xuebijing injection on the basis of the control group. The scores of CAT,APACHE Ⅱ in both two groups before and after treatment were evaluatedThe levels of C - reactive protein(CRP),procalcitonin(PCT) and T lymphocyte subsets were compared between the two groups before and after treatment. Results The levels of CD +3 ,CD +4 and CD +4 / CD +8 in the peripheral blood of patients with AECOPD were (0. 64 ± 0. 10)％ ,(0. 33 ± 0. 14)％ and (0. 95 ± 0. 48),respectively,which of the healthy controls were (0. 70 ± 0. 10)％ , (0. 41 ± 0. 17)％ , (1. 25 ± 0. 51), respectively. There were statistically significant differences between the two groups(t = 2. 09,7. 19,2. 32,all P < 0. 05). After treatment,the scores of CAT and APACHE Ⅱ in the observation group were (13. 2 ± 3. 6)points and (14. 1 ± 3. 8)points,those in the control group were (16. 6 ± 4. 1) points and (16. 9 ± 4. 2) points. The scores of CAT and APACHE Ⅱ in the two groups after treatment were lower than those before treatment(observation group: t = 3. 08,13. 25,control group: t = 2. 94,11. 31,all P < 0. 05). There were significant differences in CAT and APACHE Ⅱ scores between the two groups after treat-ment(t = 8. 90,3. 27,all P < 0. 05). The levels of CRP,PCT,CD +3 ,CD +4 and CD +4 / CD +8 in the control group were (22. 4 ± 8. 8)mg/ L,(0. 9 ± 0. 6)μg/ L,(0. 67 ± 0. 09)％ ,(0. 36 ± 0. 13)％ ,(1. 12 ± 0. 50),respectively,which in the observation group were (15. 6 ± 6. 3)mg/ L,(0. 5 ± 0. 6)μg/ L,(0. 72 ± 0. 82)％ ,(0. 43 ± 0. 13)％ ,(1. 43 ± 0. 47),respectively. The differences between the two groups were statistically significant(t = 2. 75,6. 16,2. 03,2. 69, 4. 90,all P < 0. 05). Conclusion Patients with AECOPD have immune dysfunction. Xuebijing injection is effective in the treatment of patients with AECOPD. The mechanism may be related to the regulation of immune function.
ABSTRACT
Objective To investigate the mRNA and protein expression of GPX3 gene in non-small cell lung cancer (NSCLC) patients, and then discuss the clinical significance of GPX3 in NSCLC patients. Methods Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect the GPX3 mRNA and protein levels in NSCLC tissues and adjacent non-cancerous normal lung tissues from 60 patients undergoing surgical treatment. The correlation between the expression levels of GPX3 and clinicopathological features was analyzed. Results The relative expression value of GPX3 mRNA was higher in adjacent non-cancerous tissues than in non-small cell lung cancer tissue (P < 0.05). GPX3 mRNA expression was significantly correlated with TNM stage、differentiation and lymph node metastasis. The integral optical density value of GPX3 protein confirmed was lower in adjacent non-cancerous tissues than in non-small cell lung cancer tissues (P < 0.05). In additional, the expression of GPX3 was related to TNM stage and lymph node metastasis. Conclusion The expression of GPX3 gene may play an important role in the carcinogenesis and progression of NSCLC.